Tarsus Pharmaceuticals is a clinical-stage biopharmaceutical company that develops treatments for diseases with high unmet need.
Tarsus Pharmaceuticals has raised $125.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in March 2025.
Tarsus Pharmaceuticals's investors include Vivo Capital, RTW Investments, Frazier Healthcare Partners, Visionary Venture Fund, Pharmakon Advisors.
Tarsus Pharmaceuticals is headquartered in Irvine, United States.
Tarsus Pharmaceuticals is a clinical-stage biopharmaceutical company that develops treatments for diseases with high unmet need.
Tarsus Pharmaceuticals is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Tarsus Pharmaceuticals — Funding & Investors." VCBacked, March 12, 2025, https://www.vcbacked.co/company/tarsus-pharmaceuticals. Accessed July 20, 2026.
VCBacked. (2025). Tarsus Pharmaceuticals — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/tarsus-pharmaceuticals
{{cite web |title=Tarsus Pharmaceuticals — Funding & Investors |url=https://www.vcbacked.co/company/tarsus-pharmaceuticals |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated